Welcome to our dedicated page for POMDOCTOR SEC filings (Ticker: POM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to host U.S. regulatory filings for POMDOCTOR LIMITED (NASDAQ: POM), an online medical services platform for chronic diseases in China whose American Depositary Shares trade on the Nasdaq Global Market under the symbol POM. While specific SEC filings are not listed in the available data, the company has referenced a registration statement on Form F-1 in connection with its initial public offering of ADSs.
For a foreign private issuer such as POMDOCTOR LIMITED, key SEC filings typically include a registration statement like Form F-1 for an initial public offering, followed by annual reports and other submissions that describe the company’s business, risk factors, and financial statements. These filings are relevant for understanding Pomdoctor’s Internet hospital and pharmaceutical supply chain segments, its focus on chronic disease management and pharmaceutical services, and the structure of its American Depositary Shares.
On Stock Titan, Pomdoctor’s filings page is designed to surface these documents as they become available from the EDGAR system and to pair them with AI-generated explanations. When filings such as an annual report or other disclosure documents are available, AI summaries can help clarify segment information related to the Internet hospital and pharmaceutical supply chain, as well as the company’s stated mission to provide prevention and treatment solutions for chronic diseases in China.
Users interested in POM can use this page to access Pomdoctor’s regulatory history in one place, track updates related to its ADS offering, and review how the company describes its operations, risk profile, and financial reporting in official SEC documents, once those are accessible.
POMDOCTOR LIMITED, a digital healthcare company listed on NASDAQ, describes its strategy to build a healthcare data ecosystem to support AI-powered chronic disease management and predictive healthcare services. The company aggregates real-world data from wearable devices, remote patient monitoring, physician interactions, patient health management and healthcare payment-related activities.
Management emphasizes that high-quality real-world data is a core asset for AI platforms and expects continuous data flows to improve AI models and risk analysis. Industry research cited in the report projects strong global growth in real-world data markets, driven by electronic health records, telehealth, wearable devices and demand for personalized medicine.
POMDOCTOR LIMITED, a digital healthcare company listed on Nasdaq under the symbol POM, reports that it has regained compliance with Nasdaq’s minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5450(a)(1). Nasdaq notified the company on July 10, 2026 that the matter is closed after its American Depositary Shares (ADSs) maintained a closing bid price at or above $1.00 for 10 consecutive business days from June 25 to July 9, 2026.
The company had previously received a Nasdaq notice on January 29, 2026 after its ADS closing bid price stayed below $1.00 for 30 consecutive business days. With compliance restored, POMDOCTOR’s ADSs will continue to be listed on Nasdaq, and the company continues to focus on AI-enabled and predictive healthcare solutions.
POMDOCTOR LIMITED outlined its strategy to build an AI-enabled chronic disease management ecosystem, integrating artificial intelligence, remote patient monitoring, wearable technologies and real-world healthcare data. The company aims to shift care from reactive treatment toward predictive, continuous and personalized healthcare services.
The update highlights third-party research projecting rapid growth for AI chronic disease prevention and digital chronic disease management markets over the next decade, underscoring rising demand for predictive analytics and remote monitoring solutions. Management emphasized continued investment in technology capabilities and ecosystem partnerships to support its long-term vision for predictive healthcare infrastructure.
POMDOCTOR LIMITED, a China-based digital healthcare company, has announced a strategic upgrade, repositioning itself as a foundational infrastructure provider for predictive healthcare data and services rather than a traditional online consultation platform.
The company plans to integrate wearable devices, artificial intelligence, physician resources, real-world healthcare data and healthcare payment networks into a single intelligent ecosystem. This platform is intended to support continuous monitoring, early risk identification, diagnosis, treatment, rehabilitation and long-term chronic disease management with diversified revenue streams beyond pharmaceutical sales.
POMDOCTOR describes a healthcare intelligence “flywheel” in which wearable data feed an analysis and prediction engine, inform physician intervention, and connect with insurers to support value-based care. Management highlights chronic disease trends, advances in AI and remote monitoring, and shifting reimbursement models as key drivers, and notes ambitions to expand internationally, with the United States as an important next step.
POMDOCTOR LIMITED is implementing an ADS ratio change that will take effect on June 22, 2026, U.S. Eastern Time. Each American depositary share will change from representing one-sixth of a Class A ordinary share to representing three Class A ordinary shares.
For ADS holders, this functions as a one-for-eighteen reverse ADS split: every eighteen existing ADSs will be automatically exchanged for one new ADS, with no action required by holders. No changes are being made to the underlying Class A ordinary shares.
POMDOCTOR’s ADSs are expected to begin trading on Nasdaq on a post-reverse ADS split basis under the same ticker “POM” on the effective date. The company states that the ADS trading price is expected to increase proportionally, but it gives no assurance that the post-change price will equal or exceed eighteen times the prior price.
POMDOCTOR LIMITED plans a major change to its American Depositary Share structure. Each ADS will shift from representing one-sixth of a Class A ordinary share to representing three Class A ordinary shares, effectively a one-for-eighteen reverse ADS split for ADS holders.
The company expects the ADS ratio change to take effect on or about June 22, 2026, after a post-effective amendment to its Form F-6 becomes effective. Existing ADSs held through DRS and DTC will be automatically exchanged, with eighteen current ADSs consolidated into one new ADS.
Fractional new ADS entitlements will be aggregated and sold by Citibank, N.A., the depositary bank, with net cash proceeds distributed to ADS holders. The company states that the change will not affect the underlying Class A ordinary shares, which will not be issued or cancelled, and the ADSs will continue trading on Nasdaq under the ticker “POM.”
Pomdoctor Limited reported strong top-line growth but sharply higher losses for fiscal 2025. Net revenues rose 16.7% to RMB399.9 million (US$57.2 million), driven mainly by expansion of its Internet hospital business and online pharmacy sales. Gross profit increased 9.6% to RMB52.3 million (US$7.5 million), with gross margin dipping slightly to 13.1% from 13.9%.
Operating expenses more than doubled to RMB170.9 million (US$24.4 million) as the company boosted R&D by 328.5% and incurred significant non-recurring IPO-related costs. Net loss widened to RMB130.9 million (US$18.7 million) from RMB37.4 million, and net cash used in operating activities jumped to RMB148.5 million (US$21.2 million). Pomdoctor completed a Nasdaq IPO in October 2025, raising gross proceeds of US$23.0 million, which helped lift cash and cash equivalents to RMB9.6 million (US$1.4 million) at year-end.
PomDoctor Limited filed its 2025 Form 20-F reporting rapid revenue growth but deepening losses and going-concern risk. Net revenues reached RMB399.9 million for 2025, up from RMB342.6 million in 2024 and RMB304.9 million in 2023, driven by its China-based digital healthcare platform.
The company recorded a 2025 net loss of RMB130.9 million (US$18.7 million) and negative operating cash flow of RMB148.5 million, with net current liabilities of RMB113.2 million as of December 31, 2025. Its auditor expressed substantial doubt about PomDoctor’s ability to continue as a going concern.
PomDoctor operates as a Cayman holding company relying on a variable interest entity structure in China, exposing investors to PRC regulatory, foreign exchange, data security and HFCAA-related risks that could affect its ADS listing and the value of its securities.
POMDOCTOR Ltd disclosed an initial ownership report for director Bao Wenqing. The filing identifies Bao as a director of the company but shows no reported stock transactions or derivative positions, and the transaction summary indicates zero buys, sells, exercises, gifts, or other movements.
POMDOCTOR LIMITED has changed its independent registered public accounting firm. On April 20, 2026, the company dismissed Marcum Asia CPAs LLP and appointed HYYH CPA LLC to audit its consolidated financial statements for the year ended December 31, 2025.
The company states there were no disagreements with Marcum on accounting principles, financial statement disclosure, or audit scope for the years ended December 31, 2023 and 2024, and no reportable events other than previously disclosed material weaknesses in internal control over financial reporting. These weaknesses include insufficient U.S. GAAP/SEC expertise, incomplete financial reporting policies and procedures, and weaknesses in system access security and change management.